AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
ibutilide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| class III antiarrhythmics | 1412 | 122647-31-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 100 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 7 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.34 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 8 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 12 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 26 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.60 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 7 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,IKBKB,ITK,MAP2K6,MAP3K7,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,ZAP70 | 36 | |||
| kinase-selectivity-class | AXL,CDK4,EIF2AK3,EPHB4,GRK2,INSR,MAP2K6,PDK4,TEK | 9 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 28, 1995 | FDA | PHARMACIA AND UPJOHN |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C01BD05 | CARDIOVASCULAR SYSTEM CARDIAC THERAPY ANTIARRHYTHMICS, CLASS I AND III Antiarrhythmics, class III |
| FDA EPC | N0000175426 | Antiarrhythmic |
| MeSH PA | D000889 | Anti-Arrhythmia Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| CHEBI has role | CHEBI:38070 | anti-arrhythmia drug |
Related Drugs by ATC class:
C01BD Antiarrhythmics, class III 6 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Cardioversion of Atrial Flutter | indication | ||
| Cardioversion of Atrial Fibrillation | indication | ||
| Torsades de pointes | contraindication | 31722008 | |
| Hypokalemia | contraindication | 43339004 | |
| Bradycardia | contraindication | 48867003 | |
| Prolonged QT interval | contraindication | 111975006 | |
| Hypomagnesemia | contraindication | 190855004 | |
| Heart block | contraindication | 233916004 | |
| Congenital long QT syndrome | contraindication | 442917000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 10.03 | acidic |
| pKa2 | 9.4 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | BLOCKER | IC50 | 8 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4024018 | VUID |
| N0000022023 | NUI |
| D00648 | KEGG_DRUG |
| 122647-32-9 | SECONDARY_CAS_RN |
| 4020956 | VANDF |
| 4024018 | VANDF |
| C0082966 | UMLSCUI |
| CHEBI:5856 | CHEBI |
| CHEMBL533 | ChEMBL_ID |
| DB00308 | DRUGBANK_ID |
| CHEMBL2355456 | ChEMBL_ID |
| C067192 | MESH_SUPPLEMENTAL_RECORD_UI |
| 60753 | PUBCHEM_CID |
| 7200 | IUPHAR_LIGAND_ID |
| 6642 | INN_ID |
| 2436VX1U9B | UNII |
| 41289 | RXNORM |
| 169546 | MMSL |
| 4863 | MMSL |
| d03871 | MMSL |
| 005740 | NDDF |
| 005741 | NDDF |
| 108491000 | SNOMEDCT_US |
| 108492007 | SNOMEDCT_US |
| 372500009 | SNOMEDCT_US |
| 2436VX1U9B | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Corvert | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-3794 | INJECTION, SOLUTION | 0.10 mg | INTRAVENOUS | NDA | 25 sections |
| Corvert | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-3794 | INJECTION, SOLUTION | 0.10 mg | INTRAVENOUS | NDA | 25 sections |
| Ibutilide Fumarate | Human Prescription Drug Label | 1 | 23155-326 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 20 sections |
| Ibutilide Fumarate | Human Prescription Drug Label | 1 | 23155-326 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 20 sections |